Biotech Values

[DewDiligence]

ABT’s 2Q15 sales increased 11% YoY in constant currency:

http://finance.yahoo.com/news/abbott-reports-second-quarter-2015-114500465.html

Sales of branded-generic drugs in emerging markets—including China—increased 46% YoY to $977M in constant currency; excluding acquisitions, sales of branded generics in emerging markets increased YoY at a low double-digit rate.

ABT retained 2015 non-GAAP EPS guidance of $2.10-2.20.